Medley, L., Morel, A. N., Farrugia, D., Reed, N., Hayward, N., Davies, J. M., Kirichek, O., Thakker, R.V. and Talbot, D. C. (2011) Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. British Journal of Cancer, 104(7), pp. 1067-1070. (doi: 10.1038/bjc.2011.76)
Full text not currently available from Enlighten.
Publisher's URL: http://dx.doi.org/10.1038/bjc.2011.76
Abstract
BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles. RESULTS: Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue. CONCLUSION: The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs. British Journal of Cancer (2011) 104, 1067-1070. doi: 10.1038/bjc.2011.76 www.bjcancer.com Published online 8 March 2011
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Reed, Dr Nicholas |
Authors: | Medley, L., Morel, A. N., Farrugia, D., Reed, N., Hayward, N., Davies, J. M., Kirichek, O., Thakker, R.V., and Talbot, D. C. |
College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
Journal Name: | British Journal of Cancer |
ISSN: | 0007-0920 |
University Staff: Request a correction | Enlighten Editors: Update this record